MX366309B - Composicion farmaceutica para el tratamiento de inflamacion y dolor. - Google Patents

Composicion farmaceutica para el tratamiento de inflamacion y dolor.

Info

Publication number
MX366309B
MX366309B MX2014014814A MX2014014814A MX366309B MX 366309 B MX366309 B MX 366309B MX 2014014814 A MX2014014814 A MX 2014014814A MX 2014014814 A MX2014014814 A MX 2014014814A MX 366309 B MX366309 B MX 366309B
Authority
MX
Mexico
Prior art keywords
pain
pharmaceutical composition
treating inflammation
pharmaceutically acceptable
solvate
Prior art date
Application number
MX2014014814A
Other languages
English (en)
Other versions
MX2014014814A (es
Inventor
P St Laurent Joseph
s jones Gerald
M Breese David
Original Assignee
Olatec Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Ind Llc filed Critical Olatec Ind Llc
Publication of MX2014014814A publication Critical patent/MX2014014814A/es
Publication of MX366309B publication Critical patent/MX366309B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

La presente invención está dirigida a una composición farmacéutica que comprende un portador farmacéuticamente aceptable y un compuesto de metanosulfonilalquilnitrilo, o una sal o solvato de éstos, farmacéuticamente aceptable. La presente invención también está dirigida a un método para el tratamiento de la inflamación, desórdenes relacionados con inflamación, o dolor, mediante la administración de un compuesto de metanosulfonilalquilnitrilo o sus sales o solvatos farmacéuticamente aceptables, a un paciente que lo requiere.
MX2014014814A 2012-06-05 2013-06-04 Composicion farmaceutica para el tratamiento de inflamacion y dolor. MX366309B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655891P 2012-06-05 2012-06-05
PCT/US2013/044149 WO2013184703A1 (en) 2012-06-05 2013-06-04 Pharmaceutical composition for treating inflammation and pain

Publications (2)

Publication Number Publication Date
MX2014014814A MX2014014814A (es) 2015-02-12
MX366309B true MX366309B (es) 2019-07-04

Family

ID=49671008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014814A MX366309B (es) 2012-06-05 2013-06-04 Composicion farmaceutica para el tratamiento de inflamacion y dolor.

Country Status (10)

Country Link
US (4) US20130324603A1 (es)
EP (1) EP2854786B1 (es)
JP (1) JP6178412B2 (es)
KR (1) KR102134046B1 (es)
CN (1) CN104334165B (es)
AU (1) AU2013271773B2 (es)
BR (1) BR112014030288A8 (es)
CA (1) CA2875053C (es)
MX (1) MX366309B (es)
WO (1) WO2013184703A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522878B2 (en) 2013-10-07 2016-12-20 Olatec Therapeutics Llc 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use
CA2896038C (en) * 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
EP3565540B1 (en) * 2017-01-06 2023-12-06 Olatec Therapeutics LLC A pharmaceutical composition for use in treating cardiovascular diseases
EP3768384A4 (en) * 2018-03-21 2021-11-17 Olatec Therapeutics LLC METHOD OF TREATMENT OF MELANOMAS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3427387A (en) * 1964-01-09 1969-02-11 Norwich Pharma Co Antibacterial composition containing 5-nitro-2-furyl-1,2,4-triazoles
DE3041155A1 (de) 1980-10-31 1982-06-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
DE3249054T1 (de) 1981-10-16 1983-11-17 Abbott Laboratories, 60064 North Chicago, Ill. (1-(2-benzoxazolyl)-hydrazino)-alkylnitril-derivate
US5175192A (en) * 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US5218001A (en) * 1984-03-19 1993-06-08 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
GB8916722D0 (en) 1988-08-18 1989-09-06 Ici Plc Heterocyclic compounds
KR910018021A (ko) * 1990-04-03 1991-11-30 더 록펠러 유니버시티 단백질의 글리코실화 진행 억제제 및 그 이용 방법
JPH05310565A (ja) * 1990-04-03 1993-11-22 Univ Rockefeller 蛋白質の高度グリコシル化抑制組成物及び抑制方法
US5348838A (en) 1991-07-31 1994-09-20 Kabushiki Kaisha Toshiba Photosensitive composition comprising alkali soluble binder and photoacid generator having sulfonyl group
US6362205B2 (en) * 1998-11-05 2002-03-26 Novo Nordisk A/S Substituted 3,3-diamino-2-propenenitriles, their preparation and use
US6551615B1 (en) 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
US7423064B2 (en) * 2004-09-24 2008-09-09 Olatec Industries, Llc Composition for treating bacterial, viral, fungal diseases, inflammation and pain
WO2006102604A2 (en) * 2005-03-24 2006-09-28 Anacor Pharmaceuticals, Inc. Topical formulations of borinic acid antibodies and their methods of use
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2007103273A2 (en) * 2006-03-03 2007-09-13 Trustees Of Boston University Thioredoxin and thioredoxin reductase inhibitors
US20100221337A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
US20090155176A1 (en) * 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
JP5392261B2 (ja) 2008-08-12 2014-01-22 宇部興産株式会社 非水電解液及びそれを用いたリチウム電池
CA2755678A1 (en) * 2009-03-18 2010-09-23 Olatec Industries Llc Compounds for treating inflammation and pain
CN103260613B (zh) * 2010-12-15 2015-01-14 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的3-甲磺酰基丙腈
CN103071020B (zh) * 2012-12-30 2014-08-20 慧广世纪医疗技术（天津）有限公司 用于小儿气管-支气管炎、肺炎治疗的外敷软膏及其制法

Also Published As

Publication number Publication date
KR102134046B1 (ko) 2020-07-14
JP6178412B2 (ja) 2017-08-09
MX2014014814A (es) 2015-02-12
BR112014030288A2 (pt) 2017-06-27
EP2854786A1 (en) 2015-04-08
BR112014030288A8 (pt) 2021-06-22
US20130324603A1 (en) 2013-12-05
US20180353459A1 (en) 2018-12-13
CN104334165B (zh) 2017-09-05
KR20150018852A (ko) 2015-02-24
CN104334165A (zh) 2015-02-04
JP2015523987A (ja) 2015-08-20
US10751316B2 (en) 2020-08-25
WO2013184703A1 (en) 2013-12-12
CA2875053A1 (en) 2013-12-12
CA2875053C (en) 2020-07-14
AU2013271773A1 (en) 2015-01-22
AU2013271773B2 (en) 2018-03-08
EP2854786B1 (en) 2017-03-29
EP2854786A4 (en) 2015-11-11
US20210059971A1 (en) 2021-03-04
US20230372279A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2014DN09434A (es)
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MY188139A (en) Sodium channel modulators for the treatment of pain
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
AU2011328009A8 (en) Compounds and methods for treating pain
GB201209609D0 (en) New compounds
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12016502352A1 (en) Pharmaceutical composition
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
TW201613578A (en) Pharmaceutical combinations
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2015011588A (es) Tratamiento de combinacion.
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
IN2013MU03428A (es)
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.

Legal Events

Date Code Title Description
FG Grant or registration